35588-36-4

Basic information

• Product Name: 2-CHLORO-N-(2-METHYL-5-NITROPHENYL)ACETAMIDE
• Synonyms: acetamide, 2-chloro-N-(2-methyl-5-nitrophenyl)-;2-CHLORO-5'-NITRO-O-ACETOTOLUIDIDE;2-chloro-N-(2-methyl-5-nitro-phenyl)ethanamide
• CAS NO: 35588-36-4
• Molecular Formula: C₉H₉ClN₂O₃
• Molecular Weight: 228.64
• Mol File: 35588-36-4.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 406 °C at 760 mmHg
• Flash Point: 199.3 °C
• Appearance: /
• Density: 1.411 g/cm³
• Vapor Pressure: 8.43E-07mmHg at 25°C
• Refractive Index: 1.617
• CAS DataBase Reference: 2-CHLORO-N-(2-METHYL-5-NITROPHENYL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-N-(2-METHYL-5-NITROPHENYL)ACETAMIDE(35588-36-4)
• EPA Substance Registry System: 2-CHLORO-N-(2-METHYL-5-NITROPHENYL)ACETAMIDE(35588-36-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 35588-36-4(Hazardous Substances Data)

Usage

General Description

2-CHLORO-N-(2-METHYL-5-NITROPHENYL)ACETAMIDE is a chemical compound that is derived from acetamide. It is characterized by the presence of a chloro group and a nitro group on a phenyl ring, as well as a methyl group attached to the nitrogen atom. 2-CHLORO-N-(2-METHYL-5-NITROPHENYL)ACETAMIDE may be used in various chemical and pharmaceutical applications, and its properties and reactivity make it an important building block for the synthesis of more complex organic molecules. Additionally, it is crucial to handle this chemical with care, as it may pose health hazards if not used properly, and appropriate safety measures should be taken when handling or working with it.

InChI:InChI=1/C9H9ClN2O3/c1-6-2-3-7(12(14)15)4-8(6)11-9(13)5-10/h2-4H,5H2,1H3,(H,11,13)

Upstream product

• 79-04-9 chloroacetyl chloride 
• 99-55-8 2-methyl-5-nitroaniline 

Relevant articles and documents

Discovery of 4 H-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase (ROCK) Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models

Diabetic retinopathy (DR) is a major cause of blindness, and there is a lack of effective treatment at present. Rho-associated coiled-coil containing serine/threonine protein kinases (ROCKs) have recently been suggested as potential targets for the DR treatment. We herein report the discovery of 4H-chromen-4-one derivatives as a new class of ROCK inhibitors. Structure-activity relationship analyses led to the identification of the most active compound, 4-(dimethylamino)-N-(3-{2-[(4-oxo-4H-chromen-7-yl)oxy]acetamido}phenyl) (12j). This compound showed excellent kinase selectivity for ROCK I and ROCK II against 387 other kinases. In retinal explants, compound 12j protected retinal neurons from high glucose-induced oxidative stress and apoptosis-mediated cell death. Furthermore, 12j administration suppressed the improper proliferation of Müller cells and promoted the regression of vascular vessels in retinal explants cultured in a high glucose microenvironment. Collectively, our data suggest that 12j could be a potential lead compound for the treatment of DR, hence deserving further in-depth studies.

NOVEL COMPOUNDS

The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N- [3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula(I) as described and defined herein,to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease.